Esophageal Cancer
Conditions
Interventions
Intervention group:One session of MRgRT plus four sessions of IGRT
Sponsors
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Voluntary participation with written informed consent. 2.Age >18 years. 3.Histopathologically confirmed esophageal carcinoma. 4.Resectable non-cervical esophageal cancer (cT1b–cT2 or cT3–cT4a, N0–2) assessed by multidisciplinary team. 5.Eligible for neoadjuvant chemoradiotherapy prior to surgery. 6.ECOG performance status 0–2. 7.Life expectancy >3 months. 8.No severe hematologic, cardiac, pulmonary, hepatic, renal, or immune dysfunction.
Exclusion criteria
Exclusion criteria: 1.Electronic implants (e.g., pacemakers, defibrillators, deep brain stimulators, cochlear implants). 2.Metallic foreign bodies or cerebral aneurysm clips. 3.Severe claustrophobia. 4.Prior surgery or radiotherapy to the target lesion(s). 5.History of severe allergies, significant cardiopulmonary disease, or other major systemic disorders. 6.Pregnancy or lactation. 7.Current or planned participation in other clinical trials. 8.Prior cytotoxic or biologic anticancer therapy before enrollment. 9.Participation in another clinical trial within 3 months before enrollment. 10.Inadequate organ function within 7 days before enrollment, defined as: (1)Thrombocytopenia (platelet count 3×ULN) (5)Hyperbilirubinemia (total bilirubin >1.5×ULN) Severe renal dysfunction (serum creatinine >1.7 mg/dL or >150 µmol/L) 11.Immunosuppressive disorders (e.g., HIV infection).Other malignancies (except adequately treated carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, or localized basal cell carcinoma) Autoimmune diseases,Active tuberculosis,Other clinically significant comorbidities per investigator judgment 12.Any other condition deemed ineligible by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological response rate;Progression-Free Survival ; | — |
Countries
China
Contacts
Public ContactJunYin
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China(Li Yimin, Yin Jun);;Affiliated Hospital of Sichuan Nursing Vocational College (The Third P
Outcome results
None listed